Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma

Kastritis, E; Zagouri, F; Symeonidis, A; Roussou, M; Sioni, A; Pouli, A; Delimpasi, S; Katodritou, E; Michalis, E; Michael, M; Hatzimichael, E; Vassou, A; Repousis, P; Christophoridou, A; Kartasis, Z; Stefanoudaki, E; Megalakaki, C; Giannouli, S; Kyrtsonis, M-C; Konstantopoulos, K
October 2014
Leukemia (08876924);Oct2014, Vol. 28 Issue 10, p2075
Academic Journal
Suppression of uninvolved immunoglobulins is common in multiple myeloma (MM) but the prognostic significance of this phenomenon has not been assessed. We evaluated the prognostic significance of the preservation of uninvolved immunoglobulins in 1755 consecutive, unselected, patients with newly diagnosed, symptomatic MM with pre-therapy immunoglobulin levels measured by nephelometry. Suppression of at least one uninvolved immunoglobulin was observed in 87% of patients and was more common in patients with immunoglobulin A myeloma, those aged over 65 years, in patients with advanced-International Staging System (ISS) stage, extensive-bone marrow infiltration, anemia, low platelet counts, high levels of serum M-monoclonal protein or renal dysfunction. Patients with preserved immunoglobulins had a better survival than patients with suppressed immunoglobulins (median survival 55 vs 41.5 months, P<0.001). In multivariate analysis, preservation of uninvolved immunoglobulins was independently associated with better survival (hazard ratio: 0.781, 95% confidence interval: 0.618-0.987, P=0.039); irrespective of the treatment. In a subset of 500 patients, which were strictly followed for disease progression, preservation of uninvolved immunoglobulins was associated with a significantly longer progression-free survival (60 vs 25 months, P<0.001), independently of other common prognostic factors. In conclusion, preservation of uninvolved immunoglobulins in newly diagnosed patients with symptomatic MM was independently associated with long term disease control and improved survival.


Related Articles

  • Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT. Ak, İlknur; Onner, Hasan; Akay, Olga // Annals of Hematology;Sep2015, Vol. 94 Issue 9, p1567 

    Multiple myeloma (MM) is a disease characterized by a monoclonal plasma cell population in the bone marrow whereby osseous involvement is a predominant feature. The aim of this prospective study was to investigate the combined use of F-18 FDG and F-18 NaF PET/CT in the skeletal assessment of...

  • Myeloma Presenting as Paraparesis: A Case Report. Otu, A. A.; Njideofor, U.; Etuk, M. // British Journal of Medicine & Medical Research;5/21/2014, Vol. 4 Issue 15, p3016 

    Aim: To highlight the need to consider multiple myeloma as a probable diagnosis while evaluating a patient presenting with paraparesis and backache. Presentation of Case: A 55 year old woman presented to a hospital in Calabar, Nigeria with complaints of low back pain and progressive difficulty...

  • Absence of Kaposi’s sarcoma-associated herpesvirus (KSHV) in bone marrow cells from Japanese myeloma patients. Harada, N; Hata, H; Matsuno, F; Sonoki, T; Kuribayashi, N; Matsuzaki, H; Mitsuya, H // Leukemia (08876924);Sep99, Vol. 13 Issue 9, p1465 

    Studies the absence of Kaposi's sarcoma-associated herpesvirus (KSHV) in bone marrow cells from Japanese myeloma patients. Significance of KSHV in multiple myeloma (MM); Correlation between the pathogenesis of MM and KSHV in Europe and the U.S.; Analysis of bone marrow mononuclear cells and...

  • Generalized Necrobiotic Xanthogranuloma in a Patient with Multiple Myeloma. Jimenez Esteso, Maria; Verdu, Jose; de Paz, Francisco; Tarin, Fabian // Turkish Journal of Hematology;2014, Vol. 31 Issue 4, p435 

    The article presents a case study of a 42-year-old female with generalized necrobiotic xanthogranuloma and multiple myeloma multipl myeloma on the arm, abdomen, and chest. The patient was diagnosed with Immunoglobulin G (IgG)-kappa multiple myeloma. Laboratory analysis of the patient shows...

  • Upper Gastrointestinal Bleeding from Gastric Amyloidosis in a Patient with Smoldering Multiple Myeloma. Gjeorgjievski, Mihajlo; Purohit, Treta; Amin, Mitual B.; Kurtin, Paul J.; Cappell, Mitchell S. // Case Reports in Gastrointestinal Medicine;8/23/2015, Vol. 2015, p1 

    Amyloidosis is a common complication of patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM). This proteinaceous material can be deposited intercellularly in any organ system, including the gastrointestinal (GI)...

  • Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Gonsalves, W I; Rajkumar, S V; Gupta, V; Morice, W G; Timm, M M; Singh, P P; Dispenzieri, A; Buadi, F K; Lacy, M Q; Kapoor, P; Gertz, M A; Kumar, S K // Leukemia (08876924);Oct2014, Vol. 28 Issue 10, p2060 

    The presence of clonal circulating plasma cells (cPCs) is a marker of high-risk disease in all stages of monoclonal gammopathies. However, the prognostic utility of quantitating cPCs using multiparametric flow cytometry in multiple myeloma (MM) patients with current treatments is unknown. There...

  • p53 haploinsufficiency and functional abnormalities in multiple myeloma. Teoh, P J; Chung, T H; Sebastian, S; Choo, S N; Yan, J; Ng, S B; Fonseca, R; Chng, W J // Leukemia (08876924);Oct2014, Vol. 28 Issue 10, p2066 

    Hemizygous deletion of 17p13, which harbors the TP53 gene, has been identified in >10% of newly diagnosed multiple myeloma (MM) patients and is associated with poor prognosis. To date, there is no conclusive evidence that TP53 is the critical gene. Furthermore, the functional effect of TP53...

  • Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. Pönisch, Wolfram; Holzvogt, Bruno; Plötze, Madlen; Andrea, Marc; Bourgeois, Malvina; Heyn, Simone; Zehrfeld, Thomas; Hammerschmidt, Doreen; Schwarz, Maik; Edelmann, Thomas; Becker, Cornelia; Hoffmann, Franz; Schwarzer, Andreas; Kreibich, Ute; Gutsche, Kerstin; Reifenrath, Kolja; Winkelmann, Cornelia; Krahl, Rainer; Remane, Yvonne; Hennig, Evelin // Journal of Cancer Research & Clinical Oncology;Nov2014, Vol. 140 Issue 11, p1947 

    Introduction: Bortezomib is a proteasome inhibitor that has shown important clinical efficacy either as a single agent or in combination in patients with multiple myeloma (MM). In the present protocol, bortezomib was combined with bendamustine and prednisone, in order to assess the efficacy and...

  • Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role. D’Arena, Giovanni; Rossi, Giovanni; Laurenti, Luca; Statuto, Teodora; D’Auria, Fiorella; Valvano, Luciana; Simeon, Vittorio; Giudice, Aldo; Innocenti, Idanna; De Feo, Vincenzo; Filosa, Rosanna; Musto, Pellegrino; D'Arena, Giovanni; D'Auria, Fiorella // Journal of Immunology Research;7/14/2016, p1 

    The frequency and function of regulatory T-cells (Tregs) in multiple myeloma (MM) are still matter of debate. The percentage and absolute number of circulating Tregs (CD4(+)CD25(+high  density)CD127(-/low  density)) from 39 patients with untreated MM and 44 patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics